Category: Biolase Technology Inc.
Here's a look at some of the top funding stories for medical device companies this week: DICOM Grid raises $6M for cloud-based medical imaging systems; Welch Allyn leads $7M round for Cardiac Insight; Biolase launches $12M private placement amid internal turmoil, shares soar; Trice Medical reels in $12M, ex-Embrella founder O'Donnell
Wall Street rallies as dental laser maker Biolase raises $12 million through a private placement round, even as the company deals with an ongoing civil war involving ousted CEO Federico Pignatelli.
California-based Biolase (NSDQ:BIOL) announced today that it secured $12 million in a private placement funding round, even as the company weathers the internal tumult following the ouster of former CEO Federico Pignatelli.
Ousted Biolase CEO Federico Pignatelli launches an investigation into the device maker, saying he suspects "wrongdoing, mismanagement and corporate governance failures."
Shares of Biolase (NSDQ:BIOL) got a modest boost today, even as a company insider announced a far-reaching investigation into the company's management under the suspicion of wrongdoing.
Biolase CEO Federico Pignatelli is out after a court-ordered shake-up at Biolase.
The boardroom and C-suite at Biolase (NSDQ:BIOL) got a shake-up this week following a Delaware Supreme Court decision in a lawsuit filed by Oracle Partners earlier this year.
Biolase vows to amend its complaint after a federal judge shoots down its false advertising and defamation claims against rival dental laser maker Fotona.
A federal judge this month dismissed a Biolase (NSDQ:BIOL) lawsuit alleging false advertising and defamation by dental laser rival Fotona, but left the door open for an amended complaint.
Here's a look at some of the top Wall Street stories for medical device companies this week: Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?; M&A: Medtech makers use acquisitions to fill niches; Report: Deals in the medical device sector rose 200% in Q1; CareFusion plans $1B debt offering; Activist investor Oracle revives proxy war at Biolase.
Oracle Partners issues a public statement to announce its "disappointment" over Biolase's Q1 results, which Biolase chairman & CEO Federico Pignatelli says is more evidence of the firm's attempts to take over the dental devices company.